AstraZeneca Pharma India Limited (BOM: 506820)
India
· Delayed Price · Currency is INR 6,887.15
+118.60 (1.75%)
At close: Sep 10, 2024
AstraZeneca Pharma India Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | - | 5,056 | 5,003 | 4,484 | 3,523 | 835 | Upgrade
|
| Short-Term Investments | - | - | - | - | - | 1,690 | Upgrade
|
| Cash & Short-Term Investments | 5,056 | 5,056 | 5,003 | 4,484 | 3,523 | 2,525 | Upgrade
|
| Cash Growth | 1.05% | 1.05% | 11.58% | 27.27% | 39.54% | 45.75% | Upgrade
|
| Accounts Receivable | - | 1,531 | 1,075 | 858.9 | 851.9 | 832.1 | Upgrade
|
| Other Receivables | - | 160.4 | 105.1 | 121.8 | 56.6 | 115.7 | Upgrade
|
| Receivables | - | 1,693 | 1,181 | 981.6 | 911.2 | 955.8 | Upgrade
|
| Inventory | - | 2,279 | 1,902 | 1,402 | 1,598 | 1,652 | Upgrade
|
| Prepaid Expenses | - | 109.6 | 117.7 | 108.2 | 83.9 | 82.8 | Upgrade
|
| Other Current Assets | - | 190 | 150.4 | 80.5 | 71.1 | 208.1 | Upgrade
|
| Total Current Assets | - | 9,327 | 8,355 | 7,057 | 6,188 | 5,423 | Upgrade
|
| Property, Plant & Equipment | - | 648.4 | 701.9 | 766.9 | 849.8 | 957.7 | Upgrade
|
| Other Intangible Assets | - | 21.1 | - | - | - | - | Upgrade
|
| Long-Term Deferred Tax Assets | - | 212.5 | 206.7 | 163 | 145.3 | 146.4 | Upgrade
|
| Other Long-Term Assets | - | 568.5 | 576.6 | 574.9 | 560.1 | 497.3 | Upgrade
|
| Total Assets | - | 10,780 | 9,849 | 8,566 | 7,747 | 7,064 | Upgrade
|
| Accounts Payable | - | 1,965 | 2,279 | 1,904 | 1,784 | 2,097 | Upgrade
|
| Accrued Expenses | - | 767.2 | 852.3 | 785.3 | 736.6 | 867.4 | Upgrade
|
| Current Portion of Leases | - | 18.1 | 35.2 | 36.1 | 35.1 | 25.4 | Upgrade
|
| Current Income Taxes Payable | - | 66.6 | 24.2 | 49.4 | 56.3 | 21 | Upgrade
|
| Current Unearned Revenue | - | 490.5 | 398 | 306.9 | 128.3 | 86.2 | Upgrade
|
| Other Current Liabilities | - | 263.7 | 250.8 | 244.4 | 295 | 175.2 | Upgrade
|
| Total Current Liabilities | - | 3,571 | 3,839 | 3,327 | 3,035 | 3,272 | Upgrade
|
| Long-Term Leases | - | 27.8 | 36.9 | 50.2 | 86.3 | 93 | Upgrade
|
| Other Long-Term Liabilities | - | 17.7 | 16.6 | 26.8 | 23.3 | 23.1 | Upgrade
|
| Total Liabilities | - | 3,661 | 3,962 | 3,452 | 3,185 | 3,419 | Upgrade
|
| Common Stock | - | 50 | 50 | 50 | 50 | 50 | Upgrade
|
| Retained Earnings | - | 6,313 | 5,088 | 4,321 | 3,772 | 2,855 | Upgrade
|
| Comprensive Income & Other | - | 756.4 | 749.2 | 743 | 739.4 | 739.4 | Upgrade
|
| Shareholders' Equity | 7,119 | 7,119 | 5,887 | 5,114 | 4,562 | 3,644 | Upgrade
|
| Total Liabilities & Equity | - | 10,780 | 9,849 | 8,566 | 7,747 | 7,064 | Upgrade
|
| Total Debt | 45.9 | 45.9 | 72.1 | 86.3 | 121.4 | 118.4 | Upgrade
|
| Net Cash (Debt) | 5,010 | 5,010 | 4,931 | 4,398 | 3,402 | 2,407 | Upgrade
|
| Net Cash Growth | 1.59% | 1.59% | 12.13% | 29.27% | 41.36% | 38.92% | Upgrade
|
| Net Cash Per Share | 200.44 | 200.39 | 197.25 | 175.92 | 136.08 | 96.26 | Upgrade
|
| Filing Date Shares Outstanding | 24.98 | 25 | 25 | 25 | 25 | 25 | Upgrade
|
| Total Common Shares Outstanding | 24.98 | 25 | 25 | 25 | 25 | 25 | Upgrade
|
| Working Capital | - | 5,756 | 4,515 | 3,730 | 3,153 | 2,151 | Upgrade
|
| Book Value Per Share | 284.77 | 284.77 | 235.48 | 204.56 | 182.47 | 145.78 | Upgrade
|
| Tangible Book Value | 7,098 | 7,098 | 5,887 | 5,114 | 4,562 | 3,644 | Upgrade
|
| Tangible Book Value Per Share | 283.92 | 283.92 | 235.48 | 204.56 | 182.47 | 145.78 | Upgrade
|
| Land | - | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | Upgrade
|
| Buildings | - | 427 | 421.3 | 415.2 | 383.4 | 332.8 | Upgrade
|
| Machinery | - | 1,208 | 1,154 | 1,082 | 1,023 | 835.9 | Upgrade
|
| Construction In Progress | - | 2.7 | 13.3 | 22 | 40.2 | 242.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.